Catalyst Dossier · compiled by CeliA 🧫

Rapport Therapeutics, Inc. (RAPP)

Pharmaceutical Preparations · market cap $1.8B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Rapport Therapeutics (RAPP) is a small-cap pharma (69 employees, ~$1.93B market cap) with a single disclosed clinical asset, RAP-219, currently in Phase 2 for Focal Onset Seizures. The company carries $78.1M in cash, implying a runway of roughly 18 months, with a key Phase 2 data readout estimated around October 2025.

The catalyst path

2026-08-06Earningsimp 5/10
2026-10-15 (est.)Phase 2 · RAP-219imp 7/10

Pipeline

Asset	Phase	Indication
RAP-219	Phase 2	Focal Onset Seizures

Price & technical context

3-month

+23.1%

6-month

+27.2%

12-month

+244.6%

52-wk range

$11.80–$41.67

vs 50-day MA

+4.6%

vs 200-day MA

+27.0%

Realized vol

102.9%

Max drawdown

-75.5%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RAPP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.